Evidence map›Paper›PMID 37686919›Full record

ArticleNanomaterials (Basel, Switzerland)2023

All-in-One Photoactivated Inhibition of Butyrylcholinesterase Combined with Luminescence as an Activation and Localization Indicator: Carbon Quantum Dots@Phosphonate Hybrids.

Gulia Bikbaeva, Anna Pilip, Anastasia Egorova, Ilya Kolesnikov, Dmitrii Pankin, Kirill Laptinskiy, Alexey Vervald, Tatiana Dolenko, Gerd Leuchs, Alina Manshina

Abstract read
In one paragraph

Article in Nanomaterials (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Smart photopharmacological agents: LaVONanoscale advances · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Gulia BikbaevaInstitute of Chemistry, St. Petersburg State University, St. Petersburg 199034, Russia.
Anna PilipSt. Petersburg Federal Research Center of the Russian Academy of Sciences (SPC RAS), Scientific Research Centre for Ecological Safety of the Russian Academy of Sciences, St. Petersburg 197110, Russia.
Anastasia EgorovaSt. Petersburg Federal Research Center of the Russian Academy of Sciences (SPC RAS), Scientific Research Centre for Ecological Safety of the Russian Academy of Sciences, St. Petersburg 197110, Russia.ORCID 0000-0002-0057-4202
Ilya KolesnikovCenter for Optical and Laser Materials Research, St. Petersburg State University, St. Petersburg 199034, Russia.
Dmitrii PankinCenter for Optical and Laser Materials Research, St. Petersburg State University, St. Petersburg 199034, Russia.
Kirill LaptinskiyD.V. Skobeltsyn Institute of Nuclear Physics, M.V. Lomonosov Moscow State University, Moscow 119991, Russia.ORCID 0000-0003-2592-5942
Alexey VervaldD.V. Skobeltsyn Institute of Nuclear Physics, M.V. Lomonosov Moscow State University, Moscow 119991, Russia.ORCID 0000-0002-3789-2191
Tatiana DolenkoD.V. Skobeltsyn Institute of Nuclear Physics, M.V. Lomonosov Moscow State University, Moscow 119991, Russia.ORCID 0000-0003-2884-8241
Gerd LeuchsMax Planck Institute for the Science of Light, 91058 Erlangen, Germany.ORCID 0000-0003-1967-2766
Alina ManshinaInstitute of Chemistry, St. Petersburg State University, St. Petersburg 199034, Russia.ORCID 0000-0002-1053-6410

Funding

Russian Science Foundation 22-13-00082
6 · The paper itself

Abstract

Photopharmacology is a booming research area requiring a new generation of agents possessing simultaneous functions of photoswitching and pharmacophore. It is important that any practical implementation of photopharmacology ideally requires spatial control of the medicinal treatment zone. Thus, advances in the study of substances meeting all the listed requirements will lead to breakthrough research in the coming years. In this study, CQDs@phosphonate nanohybrids are presented for the first time and combine biocompatible and nontoxic luminescent carbon quantum dots (CQDs) with photoactive phosphonate enabling inhibition of butyrylcholinesterase (BChE), which is a prognostic marker of numerous diseases. The conjunction of these components in hybrids maintains photoswitching and provides enhancement of BChE inhibition. After laser irradiation with a wavelength of 266 nm, CQDs@phosphonate hybrids demonstrate a drastic increase of butyrylcholinesterase inhibition from 38% up to almost 100% and a simultaneous luminescence decrease. All the listed hybrid properties are demonstrated not only for in vitro experiments but also for complex biological samples, i.e., chicken breast. Thus, the most important achievement is the demonstration of hybrids characterized by a remarkable combination of all-in-one properties important for photopharmacology: (i) bioactivity toward butyrylcholinesterase inhibition, (ii) strong change of inhibition degree as a result of laser irradiation, luminescence as an indicator of (iii) bioactivity state, and of (iv) spatial localization on the surface of a sample.

Indexed as

butyrylcholinesterase inhibitioncarbon quantum dotsluminescencemultifunctional materialsphotoactivation of bioactivityphotopharmacology

Identifiers

PMID37686919
PMCPMC10489800

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.